文献速递肝病消化道肿瘤与早癌

免疫反应对肝细胞癌结局的影响:与血管形成的关联

Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.
PubMed 文献 · Hepatology · 2020-10-20

该研究基于387例接受肝切除术的肝细胞癌患者,通过免疫组化检测PD-L1、CD8和CD34,并检测可溶性PD-L1。发现PD-L1阳性表达与更差的总生存显著相关,而肿瘤浸润CD8阳性T细胞与更长生存相关,且PD-L1阳性与血管包绕肿瘤簇形成相关。

要点

  • PD-L1阳性表达是肝细胞癌不良预后的独立危险因素。
  • 肿瘤浸润CD8阳性T细胞与更好的总生存显著相关。
  • PD-L1阳性与血管包绕肿瘤簇形成显著相关。

核心结论

  • 癌细胞PD-L1表达与肝细胞癌患者不良临床结局及血管形成相关。
  • PD-L1表达联合肿瘤浸润CD8阳性T细胞状态可进一步对患者临床结局进行分类。

研究设计与样本

  • 研究纳入387例接受肝切除术的肝细胞癌患者,进行PD-L1、CD8和CD34免疫组化染色及可溶性PD-L1酶联免疫吸附检测。

主要发现

  • PD-L1阳性患者(n=76)较阴性患者(n=311)总生存显著更差(多因素风险比2.502;95%CI 1.716-3.649;P<0.0001)。
  • 肿瘤浸润CD8阳性T细胞与更长总生存显著相关(多因素风险比0.383;95%CI 0.274-0.537;P<0.0001)。
  • 基于癌细胞PD-L1表达和肿瘤浸润CD8阳性T细胞状态的分层与总生存显著相关(log-rank P<0.0001)。
  • PD-L1阳性肝细胞癌与血管包绕肿瘤簇阳性显著相关。
  • PD-L1阳性患者血清可溶性PD-L1水平显著高于PD-L1阴性患者(P=0.0158)。

临床怎么用

  • 癌细胞PD-L1表达和肿瘤浸润CD8阳性T细胞状态可能作为预测性组织生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: We investigated the prognostic value of programmed death ligand 1 (PD-L1) expression, tumor-infiltrating CD8-positive T-cell status, and their combination in hepatocellular carcinoma (HCC). Their association with PD-L1 expression and vascular formation was further explored. APPROACH AND RESULTS: Using a database of 387 patients who underwent hepatic resection for HCC, immunohistochemical staining of PD-L1, CD8, and CD34 was performed. Additionally, we undertook an enzyme-linked immunosorbent assay for soluble PD-L1. Compared with patients with HCC and PD-L1-negative expression (n = 311), patients with HCC and PD-L1-positive expression (n = 76) showed significantly worse overall survival (OS; multivariate hazard ratio, 2.502; 95% confidence interval [CI], 1.716-3.649; P < 0.0001). The presence of tumor-infiltrating CD8-positive T cells was significantly correlated with longer OS (multivariate hazard ratio, 0.383; 95% CI, 0.274-0.537; P < 0.0001). Stratification based on PD-L1 expression in cancer cells and tumor-infiltrating CD8-positive T-cell status was also significantly associated with OS (log-rank, P < 0.0001). HCC with PD-L1-positive expression was significantly correlated with positivity for vessels that encapsulated tumor clusters. Serum PD-L1 levels were significantly higher in the group of patients who had PD-L1-positive expression than in the group of patients who had PD-L1-negative expression (P = 0.0158). CONCLUSIONS: PD-L1 expression in cancer cells was associated with a poor clinical outcome and vascular formation in patients with HCC. Additionally, the combination of PD-L1 expression with tumor-infiltrating CD8-positive T-cell status enabled further classification of patients based on their clinical outcome. Thus, PD-L1 expression in cancer cells and tumor-infiltrating CD8-positive T-cell status might serve as predictive tissue biomarkers.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Itoh S, Yoshizumi T, Yugawa K, et al. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation. Hepatology. 2020. PMID: 32112577. doi:10.1002/hep.31206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。